220 patient vidofludimus calcium late treatment RCT:no change in mortality (p=1), no change in ventilation (p=1), and no change in progression (p=1). RCT 223 hospitalized COVID-19 patients showing no significant difference in mortality, ventilation, or progression with vidofludimus calcium (a DHODH inhibitor) versus placebo. Oct 2022, Infectious Diseases and Therapy, https://link.springer.com/10.1007/s40121-022-00690-0, https://c19p.org/vehreschild